Study of eloralintide for knee osteoarthritis pain in people with overweight or obesity
Treatments studied
Part of Bones, joints & muscles, Hormones & metabolism clinical trials.
This trial tests an investigational drug called eloralintide to see if it can reduce knee pain in people with osteoarthritis who also have overweight or obesity. You may be able to join if you have knee osteoarthritis, a BMI of 27 or higher, and have tried to lose weight with diet before.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have knee osteoarthritis with pain or stiffness
- Your BMI is 27 or higher (a measure of weight relative to height)
- Your weight has been stable (changed less than 5%) for the past 3 months
- You have tried to lose weight through diet at least once before
- You do not have diabetes (type 1 or type 2)
- You have not had a heart attack, stroke, or other serious heart problems in the past 3 months
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an investigational medication (orforglipron) to see if it helps people with knee arthritis lose weight. You may qualify if you have overweight or obesity and have tried dieting before without lasting success.
This study tests an injectable medication called Olatorepatide to help people with overweight or obesity lose weight. It is only for people without diabetes who meet specific body mass index (BMI) requirements.
This trial tests if an investigational drug called eloralintide can help people with obesity or overweight lose weight. It is for people who do not have type 2 diabetes and who have tried but struggled to lose weight on their own.
This trial tests an experimental drug (Eloralintide) to see if it can help with weight management. It is for people who have a body mass index (BMI) between 25 and 45 and stable weight.
This trial tests if adding eloralintide helps people who are still obese or overweight while taking weekly incretin therapy. It aims to support additional weight loss for those who haven't reached their goals.
This study tests a new medicine called eloralintide for people with type 2 diabetes who are overweight or have obesity. It aims to see if the drug can help with weight loss and blood sugar control.
Hear when a new Osteoarthritis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.